Clinical trials: Immunologic Deficiency Syndromes
HIV, HIV Infections
HIV Persistence and Viral Reservoirs
Although highly active antiretroviral therapy (HAART) decreases HIV-associated mortality, it does not to completely restore health.
- Trial name
- NCT01025427
- Testing
- Raltegravir, tenofovir/emtricitabine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Francisco
HIV/AIDS, Cancer
Web-Based Cognitive Behavioral Stress Management for Latino Sexual Minority Men Living With HIV and Cancer
This is a one year study to develop and test a culturally-tailored, web-based cognitive behavioral stress management (CBSM) intervention for Latino sexual minority men living with both HIV and cancer.
- Trial name
- C-SmartManage (NCT03993054)
- Testing
- Culturally-tailored cognitive behavioral stress management
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Miami
Acquired Immunodeficiency Syndrome, HIV Infection
Multicenter, Safety Study Of Maraviroc
To collect safety and tolerability data in a more diverse patient population of patients with HIV/Aids, who have limited therapeutic options.
- Trial name
- NCT00478231
- Testing
- Maraviroc
- Where
- 16 sites in Brazil
- Volunteers
- 209 people
- Sponsor
- ViiV Healthcare
Human Immunodeficiency Virus (HIV)
Effect of Seminal Fluid on the Colon Wall; Implications for HIV Transmission
This research is being done to learn how seminal fluid affects the lining of the colon, and whether this might make it easier for HIV to get into the body and cause infection.
- Trial name
- NCT01053741
- Testing
- Radiolabeled autologous seminal fluid, Radiolabeled Normosol-R
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Kaposi's Sarcoma, HIV Infections
Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients
This study will examine the safety and effectiveness of the experimental drug bevacizumab for treating both non-acquired immune deficiency syndrome (AIDS) and AIDS-associated Kaposi's sarcoma (KS).
- Conditions
- Kaposi's Sarcoma, HIV Infections, HIV Seronegativity
- Trial name
- NCT00055237
- Testing
- Bevacizumab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Primary Immunodeficiency Diseases (PID)
A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants
The main aim of the study is to check side effect from the study treatment with TAK-771 in long term. Participants can have taken part in the previous study TAK-771-3004 (NCT05150340).
- Trial name
- NCT05513586
- Testing
- TAK-771
- Where
- 9 sites in Japan
- Volunteers
- 15 people
- Sponsor
- Takeda
Infection, Human Immunodeficiency Virus
Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection
This 48 week, phase 2b study in 150 HIV-1 infected antiretroviral therapy experienced adult subjects consists of a dose-ranging evaluation of GSK2248761 at blinded doses of 100 mg and 200 mg once daily with a control arm of…
- Trial name
- SONNET (NCT01199731)
- Testing
- GSK2248761 100 mg once daily, GSK2248761 200 mg once daily, Etravirine
- Where
- 41 sites in United States, Belgium and 3 more
- Volunteers
- 30 people
- Sponsor
- ViiV Healthcare
Anal Neoplasm
VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2
This is a phase 2, open-label efficacy study of VGX-3100 administered by intramuscular (IM) injection followed by electroporation (EP) in adult men and women who are human immunodeficiency virus (HIV) negative with histologically…
- Trial name
- NCT03499795
- Testing
- VGX-3100, CELLECTRA™ 5PSP
- Where
- 3 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- Inovio Pharmaceuticals
HIV INFECTIONS
Immunization With HIV-1 Peptides in Adjuvant for Treatment of Patients With Chronic HIV-infection
Treatment: Immunization with a peptide-mix of 17 Clusters of Differentiation number 8 (CD8) T cell minimal epitopes and 3 Clusters of Differentiation number 4 (CD4) T cell epitopes and a new adjuvant (CAF01).
- Trial name
- HIV-VAC (NCT01009762)
- Testing
- peptide vaccine (AFO-18)
- Where
- Denmark
- Volunteers
- 11 people
- Sponsor
- Gitte Kronborg
Human Immunodeficiency Virus Type 1
A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines
The purpose of this study is to evaluate the dose-response relationship of antiviral activity after 48 weeks treatment with 3 different dose regimens of TMC278.
- Trial name
- NCT00110305
- Testing
- TMC278 25 mg, TMC278 75 mg, TMC278 150 mg
- Where
- 40 sites in United States, Argentina and 12 more
- Volunteers
- 368 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections
Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)
This is an open-label, single-sequence, multiple-dose, 3 cohort study to investigate the effects of DRV/RTV and/or ETR on the pharmacokinetics (PK) of GSK3640254 and the effects of GSK3640254 on the PK of DRV/RTV and/or ETR.
- Trial name
- NCT04630002
- Testing
- GSK3640254, Darunavir/Ritonavir (DRV/RTV), Etravirine (ETR)
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
R5 Integrase Study in HIV-1 Naive Patients
This is a pilot, open-label study of raltegravir and maraviroc in combination for the treatment of antiretroviral naïve patients.
- Trial name
- NCT01204905
- Testing
- Raltegravir and Maraviroc in combination
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Maryland, Baltimore
HIV Infection, Mitochondrial Dysfunction
Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression
The purposes of this study are to evaluate if switching an antiretroviral medication from efavirenz (EFV) to atazanavir/ ritonavir (ARV/r) will, in a 96-week period, change: 1.
- Trial name
- NCT01194856
- Testing
- Atazanavir/ritonavir, Efavirenz
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- The Cleveland Clinic
HIV Infections
Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption
The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics (PK), and antiviral activity of an antibody (called VRC01) in HIV-infected adults whose HIV was well-controlled with HIV medicines.
- Trial name
- NCT02463227
- Testing
- VRC01
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infection, Human Immunodeficiency Virus
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
This study is designed to compare the efficacy and safety of simplifying therapy from a regimen of atazanavir (ATV) + ritonavir (RTV) + tenofovir/emtricitabine (TDF/FTC) to a regimen of ATV + abacavir sulfate/lamivudine (ABC/3TC)…
- Trial name
- ASSURE (NCT01102972)
- Testing
- Reyataz + Norvir + Truvada, Reyataz + Epzicom
- Where
- 46 sites in United States, Puerto Rico
- Volunteers
- 297 people
- Sponsor
- ViiV Healthcare
HIV Infections, Pregnancy Related
Reaching 90 90 90 in Adolescents in Zambia: Using All Our SKILLZ
"SKILLZ," is a mixed methods evaluation of the Grassroots Soccer (GRS) SKILLZ Package based in Lusaka, Zambia. The package is made up of three football-based programs: (1) SKILLZ-Girl - implemented in schools as part of a 10-week…
- Conditions
- HIV Infections, Pregnancy Related, STI, Mental Health Wellness 1
- Trial name
- SKILLZ (NCT04429061)
- Testing
- SKILLZ-Girl curriculum
- Where
- Zambia
- Volunteers
- 2,153 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
HIV Infection, Alcohol Consumption
Boston ARCH 4F Intervention to Reduce Fall Risk in People With HIV and Alcohol Use
This study is being conducted to assess the acceptability and feasibility of a randomized trial of a 10 week virtual intervention to reduce fall risk in people with HIV who consume alcohol.
- Conditions
- HIV Infection, Alcohol Consumption, Falls, Accidental, Falls
- Trial name
- NCT04804579
- Testing
- Fall Prevention Intervention
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Boston University
HIV, AIDS
Kaiser Permanente HIV Cohort Study
Human Immunodeficiency Virus (HIV) infected patients in the Kaiser Permanente HIV registry wil be followed in the usual clinical care to estimate the rates of specified clinical events.
- Trial name
- NCT01339403
- Testing
- non-interventional trial
- Volunteers
- 282,368 people
- Sponsor
- ViiV Healthcare
Infection, Human Immunodeficiency Virus, HIV Infections
Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects
This is a 48-week study to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of an investigational regimen including FDA approved HIV drugs in HIV-infected pediatric subjects, ages 4 weeks to < 2 years…
- Trial name
- NCT00071760
- Testing
- GW433908, ritonavir
- Where
- 15 sites in United States, Argentina and 5 more
- Volunteers
- 59 people
- Sponsor
- ViiV Healthcare
HIV Infections, Drug Use
Scaling up an Evidence-based Intervention for Antiretroviral Therapy for PWID in Vietnam: an Implementation Trial
The purpose of this study is to compare two implementation approaches [Standard Approach (SA) vs. Tailored Approach (TA)] for scaling-up the evidence-based systems navigation and psychosocial counseling integrated intervention…
- Trial name
- SNaPR01 (NCT03952520)
- Testing
- Standard Approach (SA), Tailored Approach (TA)
- Where
- Vietnam
- Volunteers
- 1,000 people
- Sponsor
- University of North Carolina, Chapel Hill